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Original Contributions
Patients Enrolled in Large Randomized Clinical Trials of
Antiplatelet Treatment for Prevention After Transient
Ischemic Attack or Ischemic Stroke Are Not Representative
of Patients in Clinical Practice
The Netherlands Stroke Survey
Lisette Maasland, MD; Robert J. van Oostenbrugge, MD, PhD; Cees F. Franke, MD, PhD;
Wilma J.M. Scholte op Reimer, RN, PhD; Peter J. Koudstaal, MD, PhD;
Diederik W.J. Dippel, MD, PhD; for the Netherlands Stroke Survey Investigators
Background and Purpose—Many randomized clinical trials have evaluated the benefit of long-term use of antiplatelet
drugs in reducing the risk of new vascular events in patients with a recent transient ischemic attack or ischemic stroke.
Evidence from these trials forms the basis for national and international guidelines for the management of nearly all such
patients in clinical practice. However, abundant and strict enrollment criteria may limit the validity and the applicability
of results of randomized clinical trials to clinical practice. We estimated the eligibility for participation in landmark trials
of antiplatelet drugs of an unselected group of patients with stroke or transient ischemic attack from a national stroke
survey.
Methods—Nine hundred seventy-two patients with transient ischemic attack or ischemic stroke were prospectively and
consecutively enrolled in the Netherlands Stroke Survey. We applied 7 large antiplatelet trials’ enrollment criteria.
Results—In total, 886 patients were discharged alive and available for secondary prevention. Mean follow-up was 2.5
years. The annual rate of transient ischemic attack, stroke, or nonfatal myocardial infarction was 6.7%. The proportions
of patients fulfilling the trial enrollment criteria ranged from 25% to 67%. Mortality was significantly higher in
ineligible patients (27% to 41%) than in patients fulfilling enrollment criteria (16% to 20%). Rates of vascular events
were not higher in trial-eligible patients than in ineligible patients.
Conclusions—Our data confirm that patients with ischemic attack and stroke enrolled in randomized clinical trials are only
partially representative of patients in clinical practice. Use of less strict enrollment criteria could enhance “generaliz-
ability” and result in more efficient selection of patients for randomized clinical trials. (Stroke. 2009;40:2662-2668.)
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Stroke and coronary heart disease are the leading causes ofdeath and disability among adults.1 Among those who
survive ischemic stroke, the long-term risk of major vascular
events is at least 5% annually.2 In the last decades, several
treatments for the prevention of recurrent stroke and other
vascular events have been proven safe and effective.
Randomized clinical trials (RCTs) indicated that aspirin
alone reduces the relative risk of stroke and other major
vascular events by 13%.3 The addition of extended-release
dipyridamole (400 mg/d) to aspirin is expected to contrib-
ute a further 18% (9% to 26%) reduction in relative risk of
serious vascular events.4 – 6
Well-designed and well-conducted RCTs are the best
method to estimate the effect of an intervention. Evidence
from RCTs forms the basis for many general clinical
guidelines. RCTs often have strict enrollment criteria,
which mainly serve to limit the risk of complications.
Moreover, stroke prevention trials often require additional
risk factors or symptoms beyond the presenting clinical
syndrome to select patients who are at a higher risk for an
outcome event and to increase homogeneity and statistical
power. One study7 found that additional enrollment criteria
in data sets from trials conducted between 1976 and 1994
increased the risk of outcome events only slightly. The
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authors also suggested that these additional enrollment
criteria would make recruitment more difficult and might
limit external validity.
The aim of our study was to estimate the eligibility for
participation in landmark trials of antiplatelet drugs of an
unselected group of patients with stroke or transient ischemic
attack (TIA) from a national stroke survey. We assessed the
effect of additional enrollment criteria by comparing baseline
characteristics, cardiovascular event, and mortality rates be-
tween trial-eligible and trial-ineligible patients.
Methods
Study Population
The Netherlands Stroke Survey was conducted in 10 centers in The
Netherlands. The participating sites included 2 small centers (400
beds), 5 of intermediate size (400 to 800 beds), and 4 large centers
(800 beds). Two centers were university hospitals. All centers had
a neurology department, a neurologist with expertise in stroke, and a
multidisciplinary stroke team. All but one hospital had a stroke unit,
8 were participating in a regional stroke service, and 9 were equipped
for thrombolytic therapy. These institutions deliver care to approx-
imately 10% of all patients with acute stroke in The Netherlands, and
Table 1. Major Inclusion and Exclusion Criteria of Selected RCTs
ESPS-2 CAPRIE TACIP MATCH ESPRIT PRoFESS
Year of publication 1996 1996 2003 2004 2006 2008
Drug comparison ASA, DP, or both
vs placebo
Clopidogrel vs ASA Triflusal vs ASA ASA vs placebo on
top of clopidogrel
ASA vs ASA and
DP
ASA and DP vs clopidogrel
No. of participants 6602 6431 2113 7599 2739 20333
Major inclusion criteria
Age, years 18 21 40 40 No age limit 55 or 50–54*
Diagnosis Stroke or TIA Stroke Stroke or TIA Stroke or TIA Stroke or TIA Stroke
Additional criteria None None None 1 or more RF mRS 4 2 or more RF*
Inclusion time window 3 months 1 week 6 months 3 months 6 months 3/3–4 months*
6 months
Exclusion criteria
Related to diagnosis
Cerebral or subarachnoid hemorrhage Exclude Exclude Exclude Exclude Exclude Exclude
Cardiac source of embolism Exclude Exclude Exclude
Stroke cause other than atherosclerosis Exclude Exclude Exclude Exclude
Related to bleeding risk
Gastrointestinal bleeding/peptic ulcer Exclude Exclude Exclude Exclude
Bleeding disturbances Exclude Exclude Exclude
History of thrombocytopenia, neutropenia Exclude Exclude Exclude
Anemia Exclude
History of intracranial hemorrhage Exclude
Major surgery or trauma 6 weeks Exclude
Related to prognosis
Uncontrolled hypertension Exclude Exclude Exclude Exclude†
Systolic blood pressure 120 mm Hg Exclude
Uncontrolled diabetes Exclude
Severe renal dysfunction‡ Exclude Exclude Exclude Exclude
(Acute) hepatic dysfunction§ Exclude Exclude Exclude Exclude
Hyperkaliemia Exclude
Unstable AP or MI 3 months Exclude Exclude
Endarterectomy 1 month Exclude Exclude Exclude Exclude Exclude Exclude
Related to current medical conditions
Life-threatening disease Exclude Exclude Exclude Exclude Exclude Exclude
Dementia Exclude Exclude Exclude Exclude
Unconsciousness Exclude Exclude
Dysphagia Exclude
Pregnancy Exclude Exclude Exclude
Severe disability Exclude
Related to concomitant therapy
Anticoagulants Exclude Exclude Exclude Exclude Exclude Exclude
Nonsteroidal anti-inflammatory drugs Exclude Exclude Exclude
Angiotensin II receptor blocker Exclude
*Two additional risk factors and 50 to 54 years or those with strokes within 3 to 4 months.
†Systolic 180 mm Hg or diastolic 95 mm Hg.
‡Creatinine clearance 30 mL/min according to the Cockroft formula.
§Alanine aminotransferase/aspartate aminotransferase 3 upper limit.
AP indicates angina pectoris; MI, myocardial infarction; ASA, aspirin; DP, dipyridamole; mRS, modified Rankin Scale; RF, risk factor.
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their size and stroke expertise can be considered representative of
stroke care in The Netherlands.8,9
All patients who were admitted to the neurology department or
seen in the outpatient clinic with suspected acute stroke or TIA
between October 2002 and May 2003 were screened. Patients were
enrolled consecutively and prospectively if the initial diagnosis of
first or recurrent acute brain ischemia was confirmed by the
neurologist’s assessment and if symptom onset was 6 months ago.
All patients were admitted to the neurology department and were
followed throughout their hospital stay. All patients or their proxies
provided informed consent and the Medical Ethics Committees and
Review Boards of the participating hospitals approved the study.
Centers were allowed to enroll patients until a local target, propor-
tional to hospital size and compatible with an overall target of 900
patients, was reached.
Data Collection
Trained research assistants collected all data from the patients’
hospital charts within 5 days after discharge. Research assistants
worked independently of the hospital team. All data were entered
into the electronic case record form and transferred regularly to a
central database through the Internet. The overall proportion of
missing values was 0.2%. At 1 and 3 years, survival status was
obtained through the Civil Registries. In all survivors, a telephone
interview was conducted by trained research assistants based on a
structured questionnaire, which was sent to the patient in advance.
The data collectors corroborated the diagnosis by information
obtained from general practitioners and hospital discharge letters. An
experienced vascular neurologist checked all collected information
and the subsequent diagnosis. Follow-up of the last patients was
completed in December 2006. Follow-up information at 3 years,
including vital status, was complete in 86% of the patients. More
details on the study population and methods of data collection can be
found in earlier publications.8,9
Trial Selection
To compare patients in the RCTs with those enrolled in the
Netherlands Stroke Survey, we selected trials that focused only on
antiplatelet therapy for secondary prevention after a recent ischemic
stroke or TIA or trials that reported a subgroup analysis of patients
with recent TIA or ischemic stroke. Registers (Cochrane database,
Current Controlled Trials, PubMed [Medline], and EMBASE) were
systematically searched. We included multicenter international
RCTs that investigated or are still investigating antiplatelet therapy
for secondary prevention. Enrollment had to be started after 1990.
We included 6 trials: European Stroke Prevention Study 2 (ESPS-2),
Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events
(CAPRIE), Triflusal versus Aspirin in Secondary Stroke Prevention
(TACIP), Management of Atherothrombosis with Clopidogrel in
High-risk patients (MATCH), European/Australian Stroke Preven-
tion in Reversible Ischaemia Trial (ESPRIT), and Prevention Regi-
men for Effectively Avoiding Second Strokes Trial (PRoFESS).10–16
The first 3 trials assessed the effectiveness and safety of antiplatelet
agents compared with aspirin or placebo and were published before
the start of this survey.10,13,16 The results of MATCH
(aspirinclopidogrel versus clopidogrel alone).17 and ESPRIT (a
3-armed trial comparing anticoagulation with coumarin or aspirin with
dipyridamole with aspirin alone) were published during the follow-up of
our survey.4 Results of the PRoFESS study (dipyridamoleaspirin
versus clopidogrel alone) were published in 2008.18
Identifying Trial-Eligible Survey Patients
We excluded patients from the stroke survey who did not survive to
hospital discharge, because those patients are ineligible for second-
ary prevention.
Major enrollment criteria for the 6 RCTs were extracted from the
published trial protocols10–16 and summarized in Table 1.
We then distinguished 5 categories of exclusion criteria: related to
diagnosis, prognosis, bleeding risk, current medical condition, and
concomitant therapy. Exclusion criteria related to diagnosis and
prognosis form the criteria aimed at selection of patients at high risk
for (recurrent) vascular events. Exclusion criteria related to bleeding
risk, current medical condition, and concomitant therapy represent
safety criteria. We considered patients who were severely disabled
and therefore not eligible for participating in a secondary prevention
trial if they had a score on the modified Rankin Scale of 4 at
discharge, when they were living in a nursing home before hospital
admission, stay when residence after discharge was a nursing home
for permanent residence, or when patients had a severely disabling
recurrent ischemic stroke, intracerebral hemorrhage, or a hip fracture
during their hospital stay.
Table 2. Characteristics of Patients Enrolled in Randomized Trials as Compared With Trial-Eligible and Trial-Ineligible Patients in the
Netherlands Stroke Survey
Stroke
Survey
ESPS-2
1996
ESPS-2
Eligible
ESPS-2
Ineligible
CAPRIE
1996
CAPRIE
Eligible
CAPRIE
Ineligible
TACIP
2003
TACIP
Eligible
TACIP
Ineligible
MATCH
2006
MATCH
Eligible
MATCH
Ineligible
N 886 6602 556 (63%) 330 (37%) 6431 286 (32%) 600 (68%) 2107 592 (67%) 174 (33%) 7599 224 (25%) 662 (75%)
Mean age, years 68.6 66.7 66.0 72.9 64.6 67.5 69.1 64.5 67.2 70.7 66.3 69.6 68.2
Male gender 56% 58% 59% 53% 64% 58% 56% 66% 60% 52% 63% 65% 54%
History
Cerebrovascular
disease
19% 17% 24% 19% 18% 20% 22% 18% 22% 27% 42% 11%
Hypertension 58% 61% 58% 61% 65% 66% 55% 62% 60% 57% 78% 63% 58%
Hyperlipidemia 40% 23% 36% 42% 38% 41% 39% 39% 43% 34% 56% 45% 38%
Diabetes 17% 15% 15% 21% 26% 18% 17% 24% 15% 22% 68% 38% 10%
Current smoker 33% 24% 35% 30% 22% 37% 32% 31% 34% 33% 48% 33% 34%
Ischemic heart
disease
10% 35% 9% 12% 12% 9% 10% 2% 10% 10% 5% 23% 6%
Qualifying event
Stroke 62% 76% 50% 81% 100% 100% 44% 74% 48% 83% 79% 55% 64%
TIA 38% 23% 50% 19% 0% 0% 56% 26% 52% 17% 21% 46% 33%
Stroke severity
mRS 0–1–2 77% 69% 92% 51% 84% 73% 82% 91% 48% 74% 88% 73%
mRS 3–5 23% 31% 8% 49% 16% 27% 18% 9% 52% 26% 12% 27%
Bold represents significant difference (P0.05).
mRS indicates modified Rankin Scale.
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End Points
The end point was the first occurrence of nonfatal myocardial
infarction, stroke, or TIA, or death, during the follow-up period,
which extended from hospital discharge until the 3-year follow-up
visit. End points were patient-reported; confirmation was sought
from general practitioners and hospital discharge letters. Cause of
death was not registered in our survey.
Statistical Analyses
Dichotomous data are described as numbers and percentages, and
continuous data are presented as means with SDs. Comparison
between trial-eligible and trial-ineligible patients were analyzed by
2 test.
We estimated the number of patient-years at risk and combined
this with the number of first nonfatal vascular events to compute an
event rate. Data on patients who did not reach an end point were
censored on the date of the patients’ last assessment. Nonfatal event
rates and mortality rates were calculated and compared with 2 tests.
STATA10 statistical software was used for all analyses.
Results
The stroke survey population consisted of 972 patients who
were evaluated because of ischemic stroke or TIA. Of all
patients, 86 (8.8%) died before discharge, leaving 886 pa-
tients suitable for secondary prevention. In our survey, 238
(61%) of the 393 outpatients had a TIA and 60 (10%) of the
579 admitted patients had a TIA. In total, 38% of all patients
had a TIA (Table 2). Mean follow-up was 2.4 years (SD, 1.2).
In our study, 2% of the patients were lost to follow-up at 1
year and 13% at 3 years. There were no significant differ-
ences in age, risk profile, trial eligibility, mortality, or
nonfatal event rate at 1 year between patients lost and patients
with a complete follow-up at 3 years.
The demographic and clinical characteristics of the survey
population are presented in Table 2. The patients were more
often male (56%) than female and had a mean age of 68.6
(SD, 13) years (range, 21 to 95 years).
As the Figure indicates, varying proportions of patients
enrolled in the stroke survey would have qualified for
participating in the MATCH (25%), CAPRIE (32%), PRo-
FESS (39%), ESPRIT (58%), ESPS-2 (63%), and TACIP
(67%). Exclusion criteria aimed at selection of high-risk
patients of an outcome event and being severely disabled
were the most important reasons for disqualification of
patients as trial-eligible. If severely disabled patients in our
stroke survey would have been considered as trial-eligible,
the proportion of trial-eligible patients would increase by
10% to 20%.
Trial-eligible patients differed from those who did not
qualify for inclusion in a trial. Patients who did not qualify
for participation in a trial were significantly older, except
for the MATCH and PRoFESS trials. Trial-eligible pa-
tients had significantly better scores on the modified
Rankin Scale at the time of assessment for inclusion (Table
2). Consistent with the results of the selected trials, more
trial-eligible patients were male. There were no consistent
significant differences in the cardiovascular risk profile
between patients who participated in trials and those who
were trial-eligible.
Mortality rates of hospital survivors during the 3 years
follow-up period differed between study-eligible and
study-ineligible patients (Table 3). Trial-ineligible patients
had a significantly higher mortality rate, 11.4 to 18.7%/
year versus 5.4 to 9.6%/year in trial-eligible patients. The
annual rate of TIA, stroke, or nonfatal myocardial infarc-
tion was 6.7% for all 886 patients. The rates of a first
nonfatal vascular event (myocardial infarction, stroke, or
TIA) were not increased in trial-eligible patients of all
studies, except for the MATCH trial in which the trial-
eligible patients had a tendency to have a vascular event
more often.
Table 2. Continued
ESPRIT
2006
ESPRIT
Eligible
ESPRIT
Ineligible
PRoFESS
2008
PRoFESS
Eligible
PRoFESS
Ineligible
2739 511 (58%) 375 (42%) 20 333 343 (39%) 543 (61%)
63 65.5 72.8 66 68.9 68.4
66% 59% 52% 64% 59% 55%
12% 15% 25% 24% 15% 25%
60% 57% 61% 74% 65% 55%
47% 44% 34% 47% 48% 35%
19% 14% 22% 28% 16% 18%
37% 35% 31% 21% 32% 35%
7% 9% 11% 23% 21% 17%
67% 46% 83% 100% 52% 68%
33% 54% 17% 0% 48% 32%
94% 95% 52% 76% 93% 66%
6% 5% 48% 24% 7% 34%
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Discussion
Our study showed that patients enrolled in international,
multicenter RCTs of antiplatelet treatment for secondary
prevention after TIA and stroke are not fully representative of
patients treated in daily practice. After applying the trials’
inclusion and exclusion criteria to the stroke survey popula-
tion, 33% to 75% of all patients in our stroke survey were not
eligible for participation. We show also that trial-eligible
patients were younger and had a better clinical outcome than
those who did not fulfill enrollment criteria. Because only a
small proportion of patients in clinical practice are trial-
eligible, the question should be raised whether it is justified to
extrapolate the results of the RCTs to the clinic. For example,
Mant et al19 found important differences between the charac-
teristics of patients with cerebrovascular disease in primary
care with those of the participants in the Perindopril Protec-
tion Against Recurrent Stroke Study (PROGRESS) trial.20
This so-called lack of external validity or generalizability of
RCT results may be one explanation for the widespread
underuse in clinical practice of treatments that were benefi-
cial in trials and that have been recommended in guidelines.21
Our results are consistent with findings of other studies in
different clinical domains. In a review of 41 US National
Institutes of Health RCTs, an average exclusion rate of 73%
Figure. The influence of inclusion and exclusion criteria of trials investigating antiplatelet drugs for secondary prevention on the propor-
tion of eligible patients in the Netherlands Stroke Survey.
Table 3. Mortality Rates and Vascular Event Rates of Nonfatal Myocardial Infarction, Stroke, or TIA in
Trial-Eligible (E) and Trial-Ineligible (IE) Patients per Trial
N at Risk
Mortality Rate,
%/year
Rate Difference
(95% CI)
Event Rate,
%/year
Rate Difference
(95% CI)Study E IE E IE E IE
ESPS-2 556 330 9.6 12.1 2.5 (0.7–5.7) 6.3 7.7 1.4 (1.1–4.0)
CAPRIE 286 600 7.4 12.0 4.6 (1.7–7.4) 6.4 6.9 0.5 (1.9–3.0)
TACIP 592 294 7.0 18.6 11.6 (7.8–15.5) 6.5 7.4 0.9 (1.7–3.6)
MATCH 224 662 7.6 11.4 3.8 (0.7–6.8) 8.0 6.3 1.7 (4.6–1.1)
ESPRIT 511 375 5.4 18.7 13.3 (9.6–16.7) 6.1 7.8 1.7 (0.8–4.2)
PRoFESS 343 543 5.9 13.8 7.9 (5.1–10.7) 5.3 7.8 2.5 (0.1–4.8)
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was reported.22 Another study showed that of the candidates
for thrombolysis in the Copenhagen stroke study, 96% were
ineligible based on the various criteria of the relevant RCTs.23
The strength of our survey was the inclusion of a large
number of unselected and consecutively enrolled patients
from multiple hospitals in The Netherlands with a confirmed
diagnosis of TIA or stroke, leading to a cohort that is
representative of clinical stroke care in The Netherlands.
A limitation of our study is that its scope is national. Most
of the RCTs we studied enroll patients worldwide. Because of
differences between countries in methods of diagnosis and
management, our stroke survey is not completely representa-
tive of stroke care worldwide.
There was a lack of information on several minor exclusion
criteria used in the RCTs we studied. When these data would
have been available, the proportion of patients fulfilling the
enrollment criteria would have been smaller.
In our study, we aimed to distinguish between trial-eligible
and trial-ineligible patients in our clinical practice population.
We considered patients trial-eligible if they fulfilled the
inclusion criteria and had no major exclusion criteria. We
excluded patients who were severely disabled at discharge,
because they probably would not have participated in a, RCT.
If we had not done this, but strictly applied the enrollment
criteria to all our stroke survey patients, 10% to 20% more
patients would have been eligible, but in our opinion, this
would not have been realistic.
Another limitation is that end points in the register were
self-reported by patients; a telephone interview was con-
ducted by trained research assistants based on a structured
questionnaire. One could argue that, especially, the end point
TIA is not a reliable outcome with the method of outcome
ascertainment as used. However, we do not think that the use
of this not-so-robust outcome measure does distract impor-
tantly from the findings of the study.
Our results may provide an optimistic view of the repre-
sentativeness of clinical trials. Our survey involved voluntar-
ily participating hospitals and therefore the results may be
biased toward better than average practice with lower rates of
recurrent vascular events.
The possibility of early inclusion of hospitalized patients
with recent ischemic stroke, as was done in the PRoFESS
trial,18 may have biased the comparison with our cohort.
However, patients were required to be “stable” and mortality
within the first few days after stroke is mostly caused by the
index event, not by recurrent vascular events. Therefore, we
consider the risk of bias small.
In our study, we have focused on RCTs of antiplatelet
treatment for secondary prevention in patients with TIA and
stroke. This included trials that primarily included patients
with TIA/stroke or reported a subgroup of patients with
recent TIA or ischemic stroke. We chose this approach to
directly compare our results of patients with stroke with those
of patients with stroke in the trials. The Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization, Manage-
ment, and Avoidance (CHARISMA)24 and Blockade of the
glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion
(BRAVO) trials,25,26 which also investigated antiplatelets in
patients with stroke and TIA, did not report subgroup analy-
ses of patients with stroke.
A last limitation is that we could only study nonfatal
cardiovascular and cerebrovascular events, because cause of
death was not available in our data set. Because it concerns a
systematic difference, the comparison between trial-related
inclusion and exclusion criteria will not be affected.
Enrollment criteria aimed at selecting patients at high risk
of vascular events were ineffective in our survey population.
For example, the MATCH trial, which required additional
risk factors for eligibility7,27 had the lowest proportion of
study-eligible patients (25%) in our stroke survey. MATCH-
eligible patients did not have a significantly increased risk of
vascular events compared with MATCH-ineligible patients
(Table 3), but there is a trend toward more vascular events in
MATCH-eligible patients in contrast to the other trials.
Howard et al7 analyzed the consequences of requiring
additional risk factors in trials, like in the MATCH trial. They
found that additional eligibility criteria undermine generaliz-
ability. Our data indicate that ineligible patients are older,
more often female, or had a more severe stroke. To our
knowledge, no clinical trials have reported follow-up in
excluded patients. Subgroup analyses in trials are not often
reported, and individual patient meta-analyses of antiplatelet
therapy in stroke are scarce. However, so far, subgroup
analyses in trials and individual patient meta-analyses do not
raise a concern for a differential treatment effect of antiplate-
lets among these subgroups.28 This provides further argu-
ments for using wide inclusion criteria and for limiting
exclusion criteria as much as possible in Phase III RCTs.
Our results confirm that RCTs investigating antiplatelets
enroll patients who are only partially representative of the
entire spectrum of patients with TIA or stroke in clinical
practice. Furthermore, we demonstrated that currently used
enrollment criteria were not successful in selecting patients at
a high risk of a vascular event. However, the enrollment
criteria were successful in selecting patients on safety criteria.
Use of less strict enrollment criteria could result in easier,
more efficient, and valid selection of patients for RCTs.
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